Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
Jean‐Louis Vincent(Université Libre de Bruxelles), David P. Sundin, Arthur P. Wheeler(Bridge University), Rekha Garg(Therapeutics Clinical Research), James M. O’Brien(Rush University Medical Center), Xavier Wittebole(Cliniques Universitaires Saint-Luc), Benjamin Trzaskoma(MDS Associates (United States))
Cited by 41
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.7k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k